Lionco Pharmaceutical Group Co.,Ltd.

Shanghai Stock Exchange 603669.SS

Lionco Pharmaceutical Group Co.,Ltd. EBIT for the year ending December 31, 2023: USD -19.75 M

Lionco Pharmaceutical Group Co.,Ltd. EBIT is USD -19.75 M for the year ending December 31, 2023, a 25.81% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Lionco Pharmaceutical Group Co.,Ltd. EBIT for the year ending December 31, 2022 was USD -26.62 M, a -300.05% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. EBIT for the year ending December 31, 2021 was USD 13.31 M, a -57.87% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. EBIT for the year ending December 31, 2020 was USD 31.59 M, a -11.10% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. EBIT for the year ending December 31, 2019 was USD 35.53 M, a 13.97% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shanghai Stock Exchange: 603669.SS

Lionco Pharmaceutical Group Co.,Ltd.

CEO	Ms. Ling Ping Tao
IPO Date	May 28, 2015
Location	China
Headquarters	Commercial and Residential Building 2
Employees	475
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.

Key trends

Past 5 years